Lilly retira del mercado Xigris porque no demuestra efectividad en tratamiento de shock séptico
Shared by Wojciech while visiting FoxBusiness.com:
LONDON -(Dow Jones)- The European Medicines Agency or EMA has been informed of Eli Lilly’s (LLY) decision to withdraw Xigris from the market worldwide further to the 28-day mortality results from the PROWESS-SHOCK study, adding that Eli Lilly has also decided to discontinue all other ongoing clinical trials.
This email is a direct message from a friend who wants to share an item of interest with you.
This email message is powered by Gigya’s sharing technology. If you no longer wish to receive messages that are sent via Gigya’s service, please click here to remove your email address.
Gigya Inc., 1975 Landings Dr., Mountain View, CA 94043.